Radboud University Medical Center
- Country
- 🇳🇱Netherlands
- Ownership
- Private
- Established
- 1951-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.radboudumc.nl
Clinical Trials
1.1k
Trial Phases
6 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (767 trials with phase data)• Click on a phase to view related trials
Obinutuzumab Induced Decreases of PLA2R Antibodies in Membranous Nephropathy: a Pilot Study
- Conditions
- Membranous Nephropathy - PLA2R Induced
- Interventions
- First Posted Date
- 2025-09-09
- Last Posted Date
- 2025-09-09
- Lead Sponsor
- Radboud University Medical Center
- Target Recruit Count
- 20
- Registration Number
- NCT07163611
- Locations
- 🇳🇱
Department of Nephrology, Radboud University Medical Center, Nijmegen, Netherlands
Protein Supplementation and Resistance Training to Prevent Fat-Free Mass Loss Following Metabolic-Bariatric Surgery
- Conditions
- Bariatric SurgeryFat Free Mass
- First Posted Date
- 2025-09-05
- Last Posted Date
- 2025-09-05
- Lead Sponsor
- Radboud University Medical Center
- Target Recruit Count
- 400
- Registration Number
- NCT07156552
- Locations
- 🇳🇱
Nederlandse Obesitas Kliniek, Nieuwegein, Netherlands
Shorter Weaning From Invasive Ventilation With Levosimendan
- Conditions
- Mechanical VentilationWeaning Failure
- Interventions
- First Posted Date
- 2025-08-05
- Last Posted Date
- 2025-08-05
- Lead Sponsor
- Radboud University Medical Center
- Target Recruit Count
- 250
- Registration Number
- NCT07105202
- Locations
- 🇳🇱
Jeroen Bosch Ziekenhuis Stichting, 'S Hertogenbosch, Brabant, Netherlands
🇳🇱Catharina Ziekenhuis Stichting, Eindhoven, Brabant, Netherlands
🇳🇱Rijnstate Ziekenhuis Stichting, Arnhem, Gelderland, Netherlands
Virtual Reality in Electrophysiological Procedures and Device Implantation: the VR inEP Trial
- Conditions
- ArrhythmiaCardiac Implantable Electronic DeviceAblation of ArrhythmiasElectrophysiologic StudyPacemakerICD
- First Posted Date
- 2025-08-05
- Last Posted Date
- 2025-08-05
- Lead Sponsor
- Radboud University Medical Center
- Target Recruit Count
- 115
- Registration Number
- NCT07105241
Comparison of the Surgical Pleth Index and the Nociception Level Index in the Pediatric Population
- Conditions
- Nociceptive PainAnesthesiaPediatric AnesthesiaNociception Monitoring
- First Posted Date
- 2025-07-25
- Last Posted Date
- 2025-07-25
- Lead Sponsor
- Radboud University Medical Center
- Target Recruit Count
- 40
- Registration Number
- NCT07084935
- Locations
- 🇳🇱
Radboud university medical centre, Nijmegen, Gelderland, Netherlands
- Prev
- 1
- 2
- 3
- 4
- 5
- 191
- Next
News
Two New Tuberculosis Drugs Show Superior Safety Profile Over Linezolid in Phase 2b Trials
Two Phase 2b clinical trials led by LMU University Hospital Munich demonstrated that sutezolid and delpazolid, both oxazolidinone antibiotics, offer safer alternatives to linezolid for tuberculosis treatment with no cases of nerve damage or blood toxicity observed.
Philikos Initiates Phase 1/2 Trial of T-Guard for Diffuse Cutaneous Systemic Sclerosis
Philikos has enrolled the first patient in a Phase 1/2 trial evaluating T-Guard for diffuse cutaneous systemic sclerosis (dcSSc), a severe autoimmune disorder with limited treatment options.
Imec Unveils Revolutionary Miniaturized Ingestible Sensor for Non-Invasive Gut Health Monitoring
Imec has developed a highly miniaturized ingestible sensor measuring just 2.1cm in length and 0.75cm in diameter, three times smaller than existing capsule endoscopies, capable of monitoring gut health for up to a week.
Thiogenesis Launches Phase 2 Trial of TTI-0102 for MELAS, a Rare Mitochondrial Disease
Thiogenesis Therapeutics has dosed the first two patients in its Phase 2 clinical trial of TTI-0102 for MELAS, a rare inherited mitochondrial disease with no approved treatments in the EU or US.
Immunotherapy Shows Promise in Prostate Cancer with MMRd Mutation
Men with prostate cancer and the MMRd mutation experienced significantly extended progression-free survival with dual immunotherapy.
Verily Partners with Dutch Institutions to Launch Large-Scale Parkinson's Disease Study
Google's life sciences division Verily collaborates with Radboud University Medical Center and ParkinsonNet to study disease progression in 650 Parkinson's patients using advanced imaging and wearable technology.